semaglutide discontinuation Weight maintenance after of GLP-1 therapies Stopping Semaglutide: Genetics, Biomarkers &

activation of PI3K/AKT downstream pathway driving synaptogenesis and anti-apoptotic effects in hippocampus Regulatory status: not approved by the FDA or EMA

Data sources The input parameters for the benefit-harm balance modelling were the relative treatment effects of GLP-1 RAs as compared to placebo, the benefit and harm outcome incidences in untreated individuals, and preference weights (relative importance) of the outcomes.24, 25, 26, 27 A careful selection of valid and applicable evidence relevant to the given decision context is a key step in a benefit-harm analysis.28, 29, 30 The relative treatment effect and baseline risks were obtained from RCTs

[9] Krahmer N, et al

Ren G, Bhatnagar S, Hahn DJ, Kim JA

Depending on the dose you take, CoQ10 might cause insomnia